ArticleEuropean thyroid journal2025
Prevalence of endogenous normal thyroid function 3 years after hemithyroidectomy for differentiated thyroid cancer.
Article in European thyroid journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in immunotherapy for thyroid malignancies: from molecular targets to clinical outcomes.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the prevalence of endogenous normal thyroid function 3 years after hemithyroidectomy for low-risk differentiated thyroid cancer if a postoperative thyroid-stimulating hormone increase up to 4 mIU/L is accepted. Method: A retrospective review of a total of 162 Eastern Danish patients was conducted. Patients were initially followed up without levothyroxine treatment after hemithyroidectomy for differentiated thyroid cancer if thyroid-stimulating hormone was below 4 mIU/L, in accordance with the Danish treatment guideline. Patients' hospital charts were reviewed, and data on the initiation of levothyroxine treatment, pre- and postoperative thyroid-stimulating hormone, recurrence, and remnant lobe nodularity were collected. Results: A total of 143/162 (88%) did not take levothyroxine before hemithyroidectomy, with a median (interquartile range) age of 53 (43-65) years; 80% were women. During follow-up, the prevalence of endogenous normal thyroid function gradually decreased to 80, 69, and 66% after 1, 2, and 3 years. Concomitantly, hypothyroidism developed with thyroid-stimulating hormone >4.0 mIU/L in 20, 31, and 34% of patients, who were replaced with levothyroxine. In patients not on levothyroxine, TSH was significantly increased within the normal range 1, 2, and 3 years after hemithyroidectomy for DTC (P < 0.0001). 4/143 (3%) had completion thyroidectomies due to growth of preexisting nodules; no patient had a recurrence. Conclusion: One-third of differentiated thyroid cancer patients require levothyroxine treatment 3 years after hemithyroidectomy if postoperative thyroid-stimulating hormone levels up to 4 mIU/L are accepted. Avoidance of levothyroxine treatment happens at the expense of a significant increase in thyroid-stimulating hormone levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.